The Physical AI Shift in Post-Acute Care: Inside Inspiren's $500M+ Bet
Dr. Dereck Mush, MD, MBA
Basalt
AI-assisted referral review for post-acute admissions teams.
Basalt is known for aI-assisted referral review for post-acute admissions teams. It is at the Series A stage with $24.5M raised and sits in our Hospital Operations category.
What they do
Basalt reads incoming post-acute referral packets and checks clinical and payer information against a facility’s admission criteria. It surfaces findings with source references for intake teams to review; a clinician makes the final admission decision. The company announced a $20 million Series A on September 24, 2026, bringing total funding to about $24.5 million.
The record
- Vertical
- Hospital Operations
- Sub-segment
- Post-acute admissions
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Not disclosed
- Region
- North America
- Founded
- Not disclosed
- Total funding
- $24.5M raised
Notable investors: New Enterprise Associates, Frist Cressey Ventures, 25m Health.
Also in Hospital Operations
More in Hospital Operations: Hospital Operations startups/HealthTech startup database
Related on The Signal
Dr. Dereck Mush, MD, MBA
The Post-REMS Long-Acting Psychiatric Revolution: How Subcutaneous Copolymer Delivery Unlocks Olanzapine Outpatient Economics
Dr. Dereck Mush, MD, MBA
De Novo AI in the Acute Care Pathway: How Queen of Hearts Redefines Emergency Triage Economics and Cath Lab Utilization
Dr. Dereck Mush, MD, MBA
Ambient ED at Scale: Leeds, TORTUS, and What UK Trusts Will Demand Next
Dr. Dereck Mush, MD, MBA